Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.59 |
| ▸ | MET | P08581 | 10/20 | 0.59 |
| ▸ | EGFR | P00533 | 5/20 | 0.59 |
| ▸ | KIT | P10721 | 4/20 | 0.59 |
| ▸ | AXL | P30530 | 4/20 | 0.59 |
| ▸ | IGF1R | P08069 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | MST1R | Q04912 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | FLT4 | P35916 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479914 | 0.93 | MET (0.63) | KDRMETEGFRKITAXL | |
| SCHEMBL4474426 | 0.93 | KDR (0.59) | KDRMETEGFRKITAXL | |
| Hydrochloric Acid SCHEMBL4473428 | 0.93 | MET (0.62) | KDRMETEGFRKITAXL | |
| SCHEMBL4477592 | 0.92 | KDR (0.61) | KDREGFRFLT1FLT4 | |
| SCHEMBL4482167 | 0.91 | KDR (0.58) | KDRMETEGFRKITAXL | |
| SCHEMBL4468963 | 0.91 | KDR (0.60) | KDRMETEGFRKITAXL | |
| SCHEMBL4477063 | 0.91 | KDR (0.57) | KDRMETEGFRKITAXL | |
| Hydrochloric Acid SCHEMBL4472072 | 0.90 | KDR (0.59) | KDRMETEGFRKITAXL | |
| SCHEMBL4469351 | 0.90 | MET (0.59) | KDRMETEGFRKITAXL | |
| SCHEMBL4472967 | 0.89 | PDGFRA (0.60) | KDRMETEGFRPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1566379-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-24 | — | — | EP | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | KDR 211/4885MET 6/4885EGFR 16/4885 |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | KDR 148/4885MET 37/4885EGFR 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.